Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 13,388,343 $ 3,286,236
General and administrative 3,908,682 5,230,923
Total operating expenses 17,297,025 8,517,159
Operating loss (17,297,025) (8,517,159)
Other income (expense), net:    
Other income (expense), net 229,507 (193,351)
Interest income (expense), net (678,022) (458,909)
Change in fair value of derivative liability 0  
Foreign currency exchange gain (loss), net 728 (267,823)
Other income (expense), net (447,787) (920,083)
Net loss $ (17,744,812) $ (9,437,242)
Net loss per share ,basic $ (4.24) $ (2.26)
Net loss per share, diluted $ (4.24) $ (2.26)
Weighted average number of common shares outstanding-basic 4,181,556 4,170,043
Weighted average number of common shares outstanding, diluted 4,181,556 4,170,043
Comprehensive loss:    
Net loss $ (17,744,812) $ (9,437,242)
Other comprehensive income (loss):    
Change in unrealized gain (loss) on marketable debt securities 57,623 (107,248)
Total other comprehensive income (loss) 57,623 (107,248)
Total comprehensive loss $ (17,687,189) $ (9,544,490)